# AMG 745 in Subjects With Age-associated Muscle Loss

> **NCT00975104** · PHASE2 · WITHDRAWN · sponsor: **Amgen**

## Conditions studied

- Age-associated Muscle Loss

## Interventions

- **DRUG:** AMG 745 0.3 mg/kg
- **DRUG:** AMG 745 1.0 mg/kg
- **DRUG:** AMG 745 3.0 mg/kg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00975104
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2010-04
- **Primary completion:** 2011-05
- **Final completion:** 2011-08
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Amgen has chosen at this time not to continue with AMG 745 study 20080733
- **Last updated:** 2018-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00975104

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00975104, "AMG 745 in Subjects With Age-associated Muscle Loss". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00975104. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*